Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The HeartSpare Study (Stage I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02794324
Recruitment Status : Completed
First Posted : June 9, 2016
Last Update Posted : June 9, 2016
Sponsor:
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust

Brief Summary:

Radiotherapy (RT) has a major curative role in women with early breast cancer, and is recommended routinely after lumpectomy and selectively after mastectomy. It has contributed to a halving of breast cancer mortality in the UK over the last 2 decades despite ever-rising cancer incidence. RT in women with left-sided tumours often exposes the underlying heart to a damaging dose. The heart is very sensitive to RT, and there were 1-2 deaths from heart disease for every 100 breast cancer patients treated during the 1960s-70s. The situation has improved in recent years, but standard RT techniques still deliver significant radiation doses to heart tissue.

Two potentially simple techniques reduce heart dose. In one, women are taught to breathe in deeply and to hold their breath for about 20 seconds while RT is given. The downward movement of the diaphragm pulls the heart away from the RT beam. In the other technique, women lie on their fronts, instead of on their backs as they normally do for breast RT. In this position, the breast falls away from the rib cage and reduces exposure of the heart. Neither technique is routinely available to women receiving breast RT in the UK for reasons that this research aims to address. The investigators need to: 1) confirm that patient position can be reproduced with millimetre precision every day using these techniques, 2) minimise costs of equipment, time and personnel required to support such techniques, 3) select the most appropriate technique for different patients and 4) train staff in centres across the UK to deliver techniques safely and effectively. By addressing all of these issues, the study aims ultimately to make heart-sparing RT available to all UK women that might benefit from treatment, thereby significantly reducing the burden of heart disease in breast cancer survivors.


Condition or disease Intervention/treatment Phase
Breast Cancer Procedure: Voluntary deep-inspiratory breath hold Procedure: Active-breathing-controlled deep-inspiratory breathhold Procedure: Prone treatment Device: Active-breathing-controlled deep-inspiratory breathhold Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Optimisation and Individualisation of Heart-Sparing Breast Radiotherapy Techniques (The HeartSpare Study)
Study Start Date : February 2012
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Voluntary deep-inspiratory breath hold
Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
Procedure: Voluntary deep-inspiratory breath hold
Patients undergoing scanning in v_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.

Active Comparator: Active-breathing-controlled deep-inspiratory breathhold
Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
Procedure: Active-breathing-controlled deep-inspiratory breathhold
Patients undergoing scanning in ABC_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC_DIBH, CT images will be obtained.

Device: Active-breathing-controlled deep-inspiratory breathhold
The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
Other Name: Active Breathing Coordinator (Elekta, Crawley, UK)

Active Comparator: Prone treatment
Stage 1B: Optimised supine DIBH vs prone position
Procedure: Prone treatment
Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.




Primary Outcome Measures :
  1. Interfraction reproducibility of chest wall position (group A) [ Time Frame: End of radiotherapy (3-4 weeks) ]
    The position of ipsilateral chest wall will be compared between the digitally reconstructed radiographs (derived from the planning CT) and the on-treatment electronic portal images and mean daily displacements calculated.

  2. Difference in mean left anterior descending coronary artery (LAD) mean normal tissue dose (NTDmean) (group B) [ Time Frame: End of radiotherapy (3-4 weeks) ]
    Using dose-volume histograms (DVHs) based on the planning scan and on-treatment CBCT imaging, mean LAD NTDmean will be compared for ABC_DIBH versus prone positioning.


Secondary Outcome Measures :
  1. Difference in NTDmean for heart, LAD, ipsilateral and whole lungs (group A) [ Time Frame: End of radiotherapy (3-4 weeks) ]
  2. Comparison of standard deviation in mean LAD NTDmean over a treatment course (group B) [ Time Frame: End of radiotherapy (3-4 weeks) ]
  3. Comparison of individual patient heart NTDmean differences by anatomical factors (group B) [ Time Frame: End of radiotherapy (3-4 weeks) ]
  4. Difference in mean normal tissue doses (NTDmean) to heart, ipsilateral and whole lungs (group B) [ Time Frame: End of radiotherapy (3-4 weeks) ]
  5. Difference in volumes of chest wall receiving 20Gy (Groups A and B) [ Time Frame: End of radiotherapy (3-4 weeks) ]
  6. Interfraction reproducibility of chest wall position (groups A and B) [ Time Frame: End of radiotherapy (3-4 weeks) ]
  7. Interfraction reproducibility of tumour bed position (groups A and B) [ Time Frame: End of radiotherapy (3-4 weeks) ]
  8. Time and equipment costs (groups A and B) [ Time Frame: End of study (2 years) ]
  9. Patient and radiographer satisfaction with positioning technique (groups A and B) [ Time Frame: Weekly questionnaire ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Complete microscopic excision of early stage invasive ductal or lobular carcinoma (pT1-3b N0-1 M0) of the left breast following breast conservation surgery or mastectomy.
  • Recommendation for whole breast (groups A and B) or chest wall (Group A only) radiotherapy (with or without tumour bed boost)
  • Age ≥18
  • Performance status ≤1
  • Patients able to tolerate breath-hold

Exclusion Criteria:

  • Requirement for nodal irradiation
  • Patients with micro- or macro-scopic disease on sentinel node biopsy who have not undergone completion axillary node clearance
  • Previous radiotherapy to any region above the diaphragm

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02794324


Locations
Layout table for location information
United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom, SM2 5PT
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Investigators
Layout table for investigator information
Principal Investigator: Anna Kirby Royal Marsden NHS Foundation Trust
Layout table for additonal information
Responsible Party: Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT02794324    
Other Study ID Numbers: CCR3593
First Posted: June 9, 2016    Key Record Dates
Last Update Posted: June 9, 2016
Last Verified: June 2016